Antidepressant-like effects of Δ9-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression
Highlights
► Antidepressant-like behavioural properties of both THC and rimonabant in OB rats. ► In intact rats THC increased BDNF but rimonabant had no effect. ► In intact rats rimonabant and THC increased the levels of p-ERKs1/2. ► Neither THC nor rimonabant altered expression of BDNF or pERK in the OB rats.
Introduction
It is estimated by the WHO that depression will be the most important cause of disability in the world by the year 2020 (Murray and Lopez, 1997). The current treatments for depression are only partially effective (Post et al., 2010), necessitating the development of alternative pharmacotherapies. Retrospective studies in cannabis users and small clinical trials have suggested possible therapeutic benefit of cannabinoid use in depression (Gruber et al., 1996). However, other previous studies have suggested that cannabis use may be a contributory cause of depression and suicidal behaviours (Bovasso, 2001). These human findings have their counterpart in animal studies, but the situation is complicated by reports of cannabinoid receptor agonists and antagonists displaying both anxiolytic- and anxiogenic-like effects in rodent models of anxiety and depression (Bambico et al., 2007, Berrendero and Maldonado, 2002, Griebel et al., 2005, Jiang et al., 2005, Viveros et al., 2005). Rimonabant can be classified as a CB1 antagonist but its inverse agonist properties have been well documented by in vitro pharmacological experiments (Howlett et al., 2002). Thus, its biochemical or behavioural effects generally are opposite in direction to effects produced by Δ9-THC or other CB1 agonists. Rimonabant has been investigated mainly for the treatment of obesity and associated metabolic dysregulation; however, clinical trials showed an increased incidence of psychiatric side effects, mainly anxiety and depression-like states, in obese patients which resulted in rimonabant being withdrawn from the market (Leite et al., 2009).
The involvement of the endocannabinoid system in depression is supported by pre-clinical studies such as that of Hill et al. (2008a) showing increased CB1 receptor expression and decreased endocannabinoid content in different brain regions in the chronic mild unpredictable stress model; effects that were generally reversed by chronic antidepressant administration. In transgenic animals lacking the cannabinoid CB1 receptor, there are enhanced behavioural signs of anxiety and depression and an amplified sensitivity to stressful stimuli (Aso et al., 2008). In clinical investigations, Hill et al. (2008b) demonstrated that circulating levels of endocannabinoids were significantly reduced in a population with major clinical depression. Together, these data are consistent with the hypothesis that an endogenous endocannabinoid system operates to maintain an appropriate affective state. They are also consistent with the traditional mood-elevating properties of cannabinoids and, perhaps, the anxiety and depression experienced by some patients prescribed the CB1 receptor antagonist rimonabant as an adjunct for weight reduction (Hill and Gorzalka, 2009).
Animal models of psychiatric disorders represent valuable tools for invasively studying molecular changes in brain tissue which cannot be done in patients (Licinio and Wong, 2004). Thus, olfactory bulbectomy (OB) in rodents has been proposed as a model with high predictive validity for chronic psychomotor agitated depression (Harkin et al., 2003, Kelly et al., 1997). The bilateral removal of the olfactory bulbs creates chronic behavioural, endocrine, neurotransmitter and immunological changes that are qualitatively similar to those occurring in depressed patients (Song et al., 1994a, Song et al., 1994b, van Riezen and Leonard, 1990). Moreover, in the context of the neurogenesis hypothesis of depression (Duman and Monteggia, 2006), some studies have reported that impaired cell proliferation and/or neuronal degeneration observed following olfactory bulbectomy are reduced by some antidepressants (Jaako-Movits et al., 2006, Jarosik et al., 2007, Keilhoff et al., 2006).
The aim of the present study was to investigate the behavioural and neurochemical effects of chronic administration of Δ9-tetrahydrocannabinol (Δ9-THC), the principal psychoactive plant cannabinoid, and the CB1 receptor antagonist rimonabant on intact and OB rats (as a model of depression). Our working hypothesis was that THC would show antidepressant-like activity whilst rimonabant might reflect its clinical side effects and exacerbate the effects of bulbectomy.
Section snippets
Animals
Male Lister hooded rats (n = 8–10 per group; Charles River UK) weighing 180–300 g were housed four per cage and acclimatised to the laboratory conditions for one week before the experiment. Rats were kept in a temperature-regulated (22 ± 2 °C) room and artificial lighting was provided from 0700 h to 1900 h. Food and water were available ad libitum and each animal was handled daily through the first week. Experimental testing began seven days after the acclimatisation period and was performed during the
Effect of ∆9-THC on spontaneous locomotor activity
In intact rats, chronic administration of ∆9-THC (2 mg/kg, i.p.) significantly decreased total locomotor activity (Fig. 1). Chronic treatment with the CB1 receptor antagonist rimonabant (5 mg/kg, i.p.) significantly increased total locomotor activity compared with vehicle-treated rats. Pre-treatment with rimonabant prevented the THC-induced decrease in locomotor activity. Acute administration (30 min) of THC or rimonabant had no significant effect on spontaneous locomotor activity (data not shown).
Discussion
In the present study, acute administration of THC (2.0 mg/kg) failed to affect total locomotor activity in intact animals. However, chronic THC treatment (2.0 mg/kg) in intact animals inhibited spontaneous locomotor activity and this effect was completely reversed by the cannabinoid CB1 antagonist rimonabant, perhaps indicating a role for CB1 receptors in modulating motor behaviours as previously reported (Barg et al., 1995), although a CB receptor-independent physiological antagonism due to the
Disclosure/Conflict of interest
The authors have no conflicts of interest to disclose.
Acknowledgements
The authors are grateful for the support of the Menoufia University (Egypt) and the University of Nottingham (UK) and to Clare Spicer, Liaque Latif and Stacey Knapp for technical assistance.
References (71)
- et al.
The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat
Pharmacol Biochem Behav
(2012) - et al.
Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides
Eur J Pharmacol
(1995) Effects of sertraline on regional neuropeptide concentrations in olfactory bulbectomized rats
Pharmacol Biochem Behav
(2001)- et al.
Corticosterone, choline acetyltransferase and noradrenaline levels in olfactory bulbectomized rats in relation to changes in passive avoidance acquisition and open field activity
Physiol Behav
(1986) - et al.
The effect of psychoactive drugs on plasma corticosterone levels and behavioural in the bulbectomised rat
Pharmacol Biochem Behav
(1979) - et al.
Brain TRPV1: a depressing TR(i)P down memory lane?
Trends Pharmacol Sci
(2008) - et al.
A neurotrophic model for stress-related mood disorders
Biol Psychiatry
(2006) - et al.
Impairments of ERK signal transduction in the brain in a rat model of depression induced by neonatal exposure of clomipramine
Brain Res
(2003) - et al.
Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression
Biol Psychiatry
(2008) - et al.
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
Biol Psychiatry
(2005)
A review of the relevance and validity of olfactory bulbectomy as a model of depression
Clin Neurosci Res
Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas
Neurobiol Dis
Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy
Exp Neurol
The olfactory bulbectomized rat as a model of depression: an update
Pharmacol Ther
Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity
Pharmacol Rep
Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat
Int Rev Neurobiol
Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC–cAMP pathway in chronic unpredictable mild stress of rats
Prog Neuropsychopharmacol Biol Psychiatry
Olfactory bulbectomy increases vasopressin, but not corticotropin-releasing hormone, content in the external layer of the median eminence of male rats
Neurosci Lett
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
Lancet
Neurobiology of depression
Neuron
Social threat and novel cage stress-induced sustained extracellular-regulated kinase1/2 (ERK1/2) phosphorylation but differential modulation of brain-derived neurotrophic factor (BDNF) expression in the hippocampus of NMRI mice
Neuroscience
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Life Sciences
WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT3 receptor function
Eur J Pharmacol
The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress
Behav Brain Res
Fluoxetine increases the activity of the ERK–CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress
Neurobiol Dis
The determination of the optimal dose of milnacipran in the olfactory bulbectomized rat model of depression
Pharmacol Biochem Behav
Role of the endogenous cannabinoid system in the regulation of motor activity
Neurobiol Dis
The enigmatic pharmacology of GPR55
Trends Pharmacol Sci
Activational role of cannabinoids on movement
Eur J Pharmacol
Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls
J Affect Disord
Biphasic effects of anandamide
Pharmacol Biochem Behav
Additive subthreshold dose effects of cannabinoid CB1 receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests
Eur J Pharmacol
Effects of chronic exercise and imipramine on mRNA for BDNF after olfactory bulbectomy in rat
Brain Res
Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats
Pharmacol Ther
Endocannabinoid system and stress and anxiety responses
Pharmacol Biochem Behav
Cited by (31)
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
2022, Brain, Behavior, and Immunity - HealthCitation Excerpt :In 2012, a study was conducted using rats to assess behavioral outcomes of chronic THC administration. The results indicated that THC increased BDNF and had antidepressant-like behavioral changes (Elbatsh et al., 2012). Motwani et al. (2018) discovered powerful anti-inflammatory properties of delta(8)-tetrahydocannabinol (THC)-11-oic acid (anabasum), a synthetic analog of THC, in humans.
Characterizing chronic non-suicidal self-injury and other forms of repetitive and escalating suicide behaviour as endocannabinoid-mediated pain and reward disorders
2022, Personalized Medicine in PsychiatryCitation Excerpt :Contrary to to acute administration, low repeated doses of THC (1 mg/kg/day for 5 days) in rats improves helplessness and hippocampal serotonergic signalling in the forced swim test [82]. A similar dose of THC administered over 21 days mimics antidepressant-like behaviour in an olfactory bulbectomized rat model of depression [83]. As for CBD, acute high doses (30–50 mg/kg) exert antidepressant-like effects in various rodent models of MDD as early as 30 min post-administration [84,85].
Development of a plant-produced recombinant monoclonal antibody against Δ-9-tetrahydrocannabinol (Δ9-THC) for immunoassay application
2022, Biotechnology ReportsCitation Excerpt :The main cannabinoids in cannabis are cannabidiol (CBD), cannabinol (CBN), and Δ−9-tetrahydrocannabinol (Δ9-THC). Only THC is a psychoactive compound [7]. In addition, many drug abusers are addicted to consume cannabis to obtain a high sensation.
Brain endocannabinoid signaling exhibits remarkable complexity
2018, Brain Research BulletinCitation Excerpt :Although CB1R inhibitors can exert antidepressant effects, CB1R activation is a more robust treatment than receptor inhibition. While rimonabant, a CB1R inhibitor, produces antidepressant effects, chronic treatment abolishes this effect (Elbatsh et al., 2012). Age-related neurodegeneration is associated with a reduction in Notch-1 signaling in the brain.
Zebrafish models relevant to studying central opioid and endocannabinoid systems
2018, Progress in Neuro-Psychopharmacology and Biological PsychiatryThe Cannabis Plant: Botanical Aspects
2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment